Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Breast cancer chemoprevention - a vision not yet realized.

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M, Steger G.

Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Epub 2009 Jul 20. Review.

PMID:
19686352
2.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

3.

Chemoprevention of breast cancer in postmenopausal women.

Geller BA, Vogel VG.

Breast Dis. 2005-2006;24:79-92. Review.

PMID:
16917141
4.

[Breakthrough in breast cancer chemoprevention].

Kahán Z, Thurzó L.

Orv Hetil. 2003 Mar 30;144(13):597-603. Review. Hungarian.

PMID:
12728784
5.

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.

PMID:
16621229
6.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
7.

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.

Kaufmann M, Rody A.

J Cancer Res Clin Oncol. 2005 Aug;131(8):487-94. Epub 2005 May 25. Review.

PMID:
15915367
8.
9.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
10.

Chemoprevention for high-risk women: tamoxifen and beyond.

Fabian CJ, Kimler BF.

Breast J. 2001 Sep-Oct;7(5):311-20. Review.

PMID:
11906441
11.

Chemoprevention of breast cancer.

Castrellon AB, Glück S.

Expert Rev Anticancer Ther. 2008 Mar;8(3):443-52. doi: 10.1586/14737140.8.3.443. Review.

PMID:
18366291
12.

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.

Cancer J Sci Am. 2000 Jan-Feb;6(1):13-20.

PMID:
10696733
13.

Never too late: reducing late breast cancer relapse risk.

Harbeck N.

Curr Med Res Opin. 2008 Dec;24(12):3295-305. doi: 10.1185/03007990802470639 . Review.

PMID:
18954499
14.

Prescribing extended adjuvant letrozole.

Gelmon K.

Breast. 2007 Oct;16(5):446-55. Epub 2007 Jun 4. Review.

PMID:
17544670
15.

Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.

Dodwell D, Williamson D.

Cancer Treat Rev. 2008 Apr;34(2):137-44. Epub 2007 Nov 14. Review.

PMID:
18006236
16.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
17.

Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.

Goss PE.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12.

PMID:
16730271
18.

Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).

Lo SS, Vogel VG.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):97-111. Review.

PMID:
14687600
19.

Pharmacological prevention of breast cancer: quo vadis?

Serrano D, Bonanni B, Cazzaniga M, Galli A, Gonzaga AG, Decensi A.

Breast. 2003 Dec;12(6):379-86. Review.

PMID:
14659109
20.

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

Sanford M, Plosker GL.

Drugs. 2008;68(9):1319-40. Review.

PMID:
18547136

Supplemental Content

Support Center